Literature DB >> 10941694

Attitudes of physicians regarding receiving and storing patients' genetic testing results for cancer susceptibility.

L M Wasserman1, O W Jones, J S Trombold, G R Sadler.   

Abstract

In order to determine interest in and support for a genetic counseling program for heritable cancers, a four-item questionnaire was sent to 700 physicians in San Diego County likely to encounter patients with significant family histories of cancer. Included in the questionnaire was an item requesting information about physician attitudes and practices regarding their record keeping for patient results of genetic testing for cancer susceptibility. Ninety-two questionnaires were returned for a response rate of 13%. The low response rate introduces caution when interpreting the results, particularly if the physicians most interested in the topic were the most likely to respond. In this light, of note was the marked variability found in the attitudes of respondents regarding where the results of patients' genetic testing results should be placed in relation to the medical record. Whereas one group of physicians would place the testing results into the medical record, just as they would any laboratory test result, other physicians do not even want written notice of the results in order to maintain patient confidentiality. Another group acknowledges the sensitivity of the information, but prefers to store genetic testing results separately, as they would results of HIV testing or history of psychiatric treatment. Genetic testing for cancer susceptibility is associated with patient concerns regarding confidentiality of testing results and fears of the consequences of release of this information to insurance companies. While the small and possibly biased sample must be considered when interpreting the results, the lack of consistency among physicians about where to store genetic testing results in terms of the patient medical record underscores the need for both a consensus statement and legal protection for both patient and physician. Variability in physician practices suggests that the process of obtaining informed consent for genetic testing should include a discussion with the patient about how the confidentiality of test results will be maintained.

Entities:  

Mesh:

Year:  2000        PMID: 10941694     DOI: 10.1023/a:1005112410338

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  7 in total

Review 1.  Medical records. Enhancing privacy, preserving the common good.

Authors:  A Etzioni
Journal:  Hastings Cent Rep       Date:  1999 Mar-Apr       Impact factor: 2.683

2.  Experiences and attitudes concerning genetic testing and insurance in a Colorado population: a survey of families diagnosed with fragile X syndrome.

Authors:  K J Wingrove; J Norris; P L Barton; R Hagerman
Journal:  Am J Med Genet       Date:  1996-08-09

3.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

4.  Privacy and security of personal information in a new health care system.

Authors:  L O Gostin; J Turek-Brezina; M Powers; R Kozloff; R Faden; D D Steinauer
Journal:  JAMA       Date:  1993-11-24       Impact factor: 56.272

5.  Genetic testing and insurance. The Ad Hoc Committee on Genetic Testing/Insurance Issues.

Authors: 
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

6.  Patients' attitudes about autonomy and confidentiality in genetic testing for breast-ovarian cancer susceptibility.

Authors:  J L Benkendorf; J E Reutenauer; C A Hughes; N Eads; J Willison; M Powers; C Lerman
Journal:  Am J Med Genet       Date:  1997-12-19

7.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.

Authors:  C Lerman; S Narod; K Schulman; C Hughes; A Gomez-Caminero; G Bonney; K Gold; B Trock; D Main; J Lynch; C Fulmore; C Snyder; S J Lemon; T Conway; P Tonin; G Lenoir; H Lynch
Journal:  JAMA       Date:  1996-06-26       Impact factor: 56.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.